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A B S T R A C T
The authors presents the review of the literature concerning the pathogenesis, classiﬁcation, risk factors
as well as perspectives for the treatment of age-related macular degeneration (AMD). AMD is a
progressive illness, which is the most common cause of blindness in developed countries. The
degenerative changes associated with both forms (dry and wet AMD) occur in the central part of retina,
the macula, but the exact aetiology is still not unclear. The pathogenesis of AMD includes: lipofuscine
genesis, drusogenesis, and local inﬂammatory state, as well as neoangiogenesis. Multiple studies have
assessed the role of genetic variants on AMD development and progression, especially with complement
factor H (CFH) and age-relatedmaculopathy susceptibility 2 (ARMS2) genes, the twomajor susceptibility
genes for AMD. The disease has been associated with light-induced oxidative damage, accumulation of
cholesterol and other lipids, and has been linked to systemic factors such as smoking, hypertension and
atherosclerosis. Also female gender, and a high body-mass index (BMI > 30) have been reported as the
important demographic and environmental risk factors in AMD. The neovascular form of AMD is
characterized by the formation of subretinal choroidal neovascularization (CNV) and is the cause ofmost
cases of blindness in the elders. Currently, the only approved treatment for dry AMD is the use of AREDS
formulation. In the near future, it is likely that the treatment of dry AMD will be a combination of
different drugs that will target the different pathways involved in the pathogenesis and progression of
dry AMD. Exudative AMD is treated through injections of anti-VEGF A drugs as pegaptanib or
ranibizumab and bevacizumab, which are considered the standard drugs. Aﬂibercept, or VEGF Trap-eye,
is a novel compound derived from the native VEGF receptor (VEGFR) that binds to all VEGF and VEGF-B
isoforms as well as to PlGF. It may be considered an attractive alternative to other anti-VEGF agents.
 2014 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Age-related diseases such as age-related macular degeneration
(AMD) and cataract will assume increasing importance in the
public health of the nation. AMD and cataract are both common
causes of visual acuity loss and reduced quality of life in the elderly.
Conditions may coexist that limit the ﬁnal result after cataract
surgery [1,2].
AMD is a multi-faceted condition that affects the central retina,
which ultimately leads to blindness in millions of people world-
wide. The pathophysiology and risk factors for AMD are complex,
and the symptoms manifest in multiple related but distinct forms
[3]. Untreated AMD can result in blindness, especially in white
men or women over the age of sixty with blue irises [4]. With* Corresponding author.
E-mail address: k.michalska.malecka@gmail.com (K. Michalska-Małecka).
http://dx.doi.org/10.1016/j.eurger.2014.09.007
1878-7649/ 2014 The Authors. Published by Elsevier Masson SAS. This is an open accprogressive deterioration of the macula, AMD patients experience
amultitude of visual problems that signiﬁcantly affect theirmental
health and quality of life (QoL) [5]. Visual impairment leads to
reduced QoL, poorer general health, and increased mortality
[6]. The decrease of vision is a serious risk factor for loss of balance,
perhaps leading to falls and injury. Many risk factors for falling
among elder people have been identiﬁed in epidemiological
studies, including poor vision [7].
2. Epidemiology
There are around 20 million reported patients with all kinds of
AMD, but the total number is probably 100% higher. Data from
different research centers are alarming and conﬁrm the high AMD
incidence rate [4]. The disease is more common in Caucasian
individuals than in pigmented races. In predominantly Caucasian
populations, the age-standardized prevalence of AMD in at least
one eye is 7760 cases permillion. AMD is themost important singleess article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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countries. Blindness resulting from AMD rarely occurs before age
70, andmost cases occur after age 80. The age-standardized 1-year
incidence of legal blindness resulting from AMD is 212 cases per
million [8]. In cross-sectional population-based studies La Cour
et al. found that about 45% of eyes with AMD have visual acuity
reduced to 20/200 orworse [8]. In the US, the estimated prevalence
of AMD (neovascular and/or geographic atrophy) is 1.47%, affecting
approximately 1.75 million individuals [9]. These numbers are
projected to increase by 50% by 2020 and data suggest that more
than 3 million people in the United States will be affected by the
disease by 2020 [9]. In Japan, which has the oldest and longest
living population in the world, 1.64 million people are affected by
visual impairment, of whom 61% are older than 65 years. Notably,
early AMD is highly prevalent (12.7%) in those 50 years and older in
the Japanese population, whereas late AMD is less prevalent
(0.87%) [10]. In the newest study, Owen et al. report the prevalence
of late AMD standardized to the UK population aged 50 years or
older was 2.4%, increasing to 4.8% in those aged 65 years or older,
and 12.2% in those aged 80 years or older [11]. In another study,
Jonasson et al. in Scandinavian population found a higher
prevalence of AMD in the studied group [10]. The prevalence of
early AMDwas 12.4% for those aged 66–74 years and 36% for those
aged 85 years. The authors concluded that persons aged
 85 years have a 10-fold higher prevalence of late AMD than
those aged 70–74 years [12]. Over the last few years, life
expectancy in Poland has been increasing steadily and the
forecasts for the future are optimistic. For men, this rate is
predicted to grow from the current 70.4 years to 77.6 years in 2035,
while for women, from 78.8 to 83.3 years (compared with
respectively 56.0 and 61.6 years in 1950) [13]. In Poland, the
estimated prevalence of AMD is 1.2 million people with 10–15%
prevalence of exudative form of disease and presently arrives
about 100 thousand new patient yearly. About 40–50 thousand are
legally blind because of AMD.
3. Classiﬁcation of AMD
Clinically, there are two types of AMD dry (degenerative) and
wet (neovascular) form. The latter form of AMD includes
geographic atrophy and more severe disciform (neovascular)
variant ﬁrst described in 1885 by Haab as senile macular
degeneration [14].
Dry AMD accounts for about 80% of cases affecting both eyes,
but it typically causes only mild loss of vision [15]. Geographic
atrophy (GA), the advanced non-neovascular form of AMD,
accounts for 35% of all cases of late-stage AMD and 20% of legal
blindness attributable to AMD [16]. Dry AMD, which is usually
slowly progressing, for unknown reasons can become an aggres-
sive–neovascular form of this disease. On account of the complex
character of AMD changes, there are many classiﬁcations of this
disease but the most general seems to be that shown by AREDS
[17]. According to this examination there are 4 stages of AMD
progression: initial (A), with small areas of hyperpigmentation and less than
20 middle-size druses; intermediate (B), with one or a few big druses, many middle-
size druses or geographical atrophy outside the retinal
macula; advanced (C and D), with the most progressive changes
characteristic of both dry and exudative AMD, which can occur
with or without neovascularization.
In clinical practice, the severity of AMD can be categorized
based on Snellen visual acuity (VA) testing of the better-seeing eye:mild (20/20–20/40), moderate (20/50–20/100), severe (20/200 or
worse), very severe (20/800 or worse) [18].
4. Pathogenesis and risk factors of AMD
The abnormalities of this disorder range from discrete drusen
deposits and pigmentary changes in early AMD to geographic
atrophy and/or choroidal neovascularization (CNV) in the
advanced forms. Human retina undergoes changes as part of the
natural course of aging. AMD is generally associated with
pathological changes in the retinal pigment epithelium (RPE)
and Bruch’s membrane (a collagen-rich extracellular matrix
between the RPE and choroidal vasculature) including appearance
of ophthalmoscopically visible focal yellow deposition of acellular,
polymorphous debris called drusen between the retinal pigment
epithelium and Bruch’s membrane [19]. Pathogenesis of AMD
includes: drusen genesis, lipofuscin genesis, local inﬂammatory
state genesis, as well as angiogenesis [20]. Druses are retinal
metabolites’ clusters gathered under RPE and the internal layer of
the choroid called Bruch’s membrane which handicap transport of
nutritive components and metabolites. Immune-chemical exam-
inations have shown that druses contain plasma proteins,
lipoprotein (apolipoprotein E), cholesterol-rich lipids, polysac-
charides, glycoprotein and plasma amyloid P, responsible for
complement inactivation and membrane attack complex (MAC)
formation. The complement causes intensiﬁcation of a local
inﬂammatory state and, as a consequence of this, degeneration
of photoreceptors and RPE [21]. Drusen are often classiﬁed as
‘‘hard’’ or ‘‘soft’’ (also called ‘‘large’’) and while the hard form is
common in the aging human eye, soft drusen are more closely
associated with risk and progression of AMD [22]. Amorphous
druses are heterogeneous. There are a few types of these colloid
bodies. The most common are: hard, which are hyaline deposits the size of < 65 um;
 soft, the size of > 65 um, of irregular shape, with tendency to
form bigger clusters; mixed, which appear when hard and soft druses occur
simultaneously.
Yellow deposits which appear in RPE basement membrane are
called basement lamina druses. Each druse can turn into calciﬁed
one. Drusen are also classiﬁed as small (<63 mm in diameter with
discrete margins), medium (63–124mm) or large (>125 mm with
indistinct edges) [23].
As the human organism ages, numerous metabolites appear in
the retina, which can make the process of druse formation and
lipofuscin genesis accelerate. Lipofuscin (LF), called cell-aging
factor, is a product of incompletemetabolism of external segments
of photoreceptors by phagolysosomes. Due to loss of the protein-
lipid membrane tightness, liposome lipofuscin gets into cytoplasm
and then to extracellular areas, which ﬁnally results in forming
druses [20]. Molecule LF includes hybrid ﬂurophor A2-E taking an
active part in photoreceptors’ apoptosis, which suggests that LF is
involved in AMD pathogenesis [20]. When present in excessive
levels, lipofuscin and A2-E (a toxic vitamin A dimer) damage
photoreceptors and choriocapillaris, leading to geographic atro-
phy. Besides being toxic to the RPE, A2-E has also been shown to
activate the complement cascade [24,25].
Long-term epidemiological studies have identiﬁed valuable
information on the prevalence, incidences, natural history and
associated risk factors of AMD [22]. The disease has been
associated with light-induced oxidative damage [26], accumula-
tion of cholesterol and other lipids [27], and has been linked to
systemic factors such as smoking [28], hypertension and
atherosclerosis [29,30]. Cigarette smoking is associated with
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and platelet aggregation. It is also associated with reduced plasma
high-density lipoprotein and antioxidant levels [31]. Cigarette
smoking can damage choroidal vessels and diminish choroidal
blood ﬂow through atherosclerosis. Nicotine promotes angiogen-
esis through nicotine-induced up-regulation of VEGF, a proangio-
genic factor involved in the pathogenesis of neovascular AMD
[32]. Authors found that cigarette smoking also causes inﬂamma-
tion by activating complement C3 and other inﬂammatory
mediators and reducing serum levels of complement factor H
[33]. Lee et al. found that current cigarette smoking in exudative
AMD patients is associated with a poor visual acuity improvement
following intravitreal ranibizumab therapy [34]. Cigarette smoking
increases the risk of developing AMD, with heavier smokers
showing an increasingly greater risk of advanced forms of AMD
[35]. Patients diagnosed with early AMD exhibit signs of systemic
and retinal vascular alterations that correlated with known risk
markers for future cardiovascular morbidity [36]. Signiﬁcant
choroidal vascular alterations, such as changes in choriocapillaris
density and volume and choroidal vessel diameter, have been
reported both in ageing and AMD [37]. Choroidal ischaemia is well
accepted as a causative factor, but its severity and prevalence have
not been well documented because of the difﬁculty in imaging the
choroid due to light absorption by the overlying retinal pigment
epithelium (RPE) [38]. Coleman et al. based on results of their study
found ultrasonographic evidence of choroidal ishcaemia in AMD
[38] which is consistent with the results presented by others
authors [39]. Other authors concluded that pharmacological
agents such as sildenaﬁl, tadalaﬁl, niacin or other agents that
increase choroidal perfusion could have a beneﬁcial effect on
delaying or interdicting AMD [40]. Cardiovascular risk factors, such
as hypertension and hyperlipidemia have been inconsistently
associated with AMD risk as well. Elevated serum triglycerides
were associated with increasing intermediate AMD in one series
while another population found no association with serum lipids
[41]. Apolipoprotein E (apo E) is unique among lipoproteins,
because of its special connections with nervous tissue. In the
retina, the analogue of the astrocyte, theMuller cells seem to be the
site of apo E production. Apo Emobilizes and redistributes lipids, in
maintenance and repair of neuronal cell membranes in central
nervous system (CNS) injury and neurodegenerative disorders
[42]. Apart from homeostasis of cholesterol and triglicerides, Apo E
has also other functions, e.g. immunoregulation, nerve regenera-
tion or activation of lipolic enzymes [43]. Some prior studies have
suggested a possible role of apo E polymorphism in development of
AMD. It is interesting, that authors have found a reduced risk of
AMD in peoples carrying e4 allele, whereas for other neurode-
generative disorders and cardiovascular diseases authors have
found increased risk for these subjects [44,45]. Apo E may have a
signiﬁcant role in retinal membrane renewal, and cell membrane
remodeling in macular area is probably the most important for
normal physiology and functions of the retina. Failure of this
process may be a risk for development of degenerative disorders of
the central retinal area. In other study female gender, and a high
body-mass index (BMI > 30) have been reported as the important
demographic and environmental risk factors in AMD [46,47]. There
are similarities between the drusen formation in AMD and in
formation of plaques in Alzheimer’s disease (AD). Drusen contain
similar protein components to the plaques found in AD. ApoE and
amyloid beta (Ab) are found both in AMD drusen as well in AD
plaques. The Ab found in drusen is thought to be locally derived
from the RPE cells. In the AMD inﬂammatory process, there is an
associated rise in expression of both Ab protein and acute-proteins
such as C-reactive protein (CRP) [48]. In the last decade much
interest has been focused on the connection between the function
of the antioxidative system, concentration of antioxidants and thepresence of age related diseases. The pathogenesis of dry AMD is
not completely understood and it is suggested that oxidation and
inﬂammation play important roles in the pathogenesis of the
diseases. Apart from adrenal glands, the retinal tissue is one of the
tissues with the biggest oxygen needs due to the complexity of its
metabolism processes. Processes of cellular respiration occurring
in mitochondria are a source of reactive oxygen forms (ROF) which
can damage both retinal cones and rods, especially when reductive
mechanisms are failing [49]. The human antioxidative system
consists of two parts, enzymatic and nonenzymatic part. Enzy-
matic part of the system includes: catalase, glutathione peroxidase
and reductase and superoxide dismutase [50]. Correct activity of
these systems is controlled by zinc, selenium, copper and
manganese ions. The non-enzymatic part of this system includes
vitamins E and C, glutathione as well as carotenoids, and especially
lutein and mezoxantine, which are natural components of the
macula [51]. Nowak et al. have raised a point that oxidative could
be one of the factors involved in the pathogenesis of AMD and
suggested the possible protective effect of antioxidants supple-
mentation [52]. Although the rods and cones are replaced every
10 days their outer segments may be at particular risk of the
oxidative damage because of high concentration of the poly-
unsaturated fatty acids in the photoreceptor outer segment
membrane. Docosahexaenoic acid (DHA) is an omega-3 fatty acid
that is a primary structural component of the human retina,
comprising 60% of the polyunsaturated fatty acids in the retina. It is
the most oxidizable fatty acid in the body and is found in the
membrane of the outer segment of the photoreceptors. The human
macula has a lifelong exposure to light and very high oxygen
consumption. The antioxidant index of the body, that includes the
measurement of the antioxidative enzymes activity and plasma
nonenzymatic components concentration, has been studied in
AMD patients by several researchers but the results were
contradictory [52–56]. Uruglu et al. found that there is a signiﬁcant
increase in oxidative stress in AMD patients and signiﬁcant
decrease in antioxidant defense measured by the total thiol level
and in PON1 activity [54]. Similar results were presented by other
authors who found that superoxide dismutase (SOD), gluthatione
reductase (GR) and gluthatione peroxidase (GPx) activity are
signiﬁcantly higher and serum vitamin C and total antioxidant
capacity signiﬁcantly decreased in control group than compared
with patients with AMD [55–57]. There is more andmore evidence
that vitamins with antioxidative potential (e.g, vit. A, C and E) are
one of the protective factors for vascular endothelium. They
decrease inﬂammation, inhibit platelet aggregation and progres-
sion of the atherosclerosis. The results of case-control studies
concerning supplementation with antioxidative vitamins are often
ambiguous but they generally indicate a decrease in the risk of
degenerations and cardiovascular diseases, especially if they are
given early [17,58]. In conclusion the ﬁnding of the various studies
suggests that the patients with both forms of AMD are an altered
metabolic state of oxidation-reduction and that it is convenient to
give therapeutic interventionswith antioxidants supplementation.
Inﬂammation has been hypothesized to have a role in the
pathogenesis of age-related macular degeneration (AMD)
[59]. Medzhitov ﬁrst introduced the idea of para-inﬂammation
as a tissue adaptive response to noxious stress or malfunction that
has characteristics intermediate between basal and inﬂammatory
states [60]. Para-inﬂammation has characteristics that are inter-
mediate between basal and inﬂammatory states. In the aging
retina, oxidized lipoproteins and free radicals are major causes of
tissue stress and serve as local triggers for retinal para-inﬂamma-
tion. Para-inﬂammatory responses in the retinamay be reﬂected in
microglial activation and subretinal migration, and breakdown of
blood-retinal barrier. Drusen have been shown to contain proteins
associated with immune-mediated processes and inﬂammation,
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Bruch’s membrane in AMD eyes [61]. It has been hypothesized that
infectious agent activation of an aberrantly regulated alternative
complement pathway might contribute to the development of
AMD [62]. Earlier data from a sample of a cohort study showed an
association of Chlamydia pneumoniae antibody titers with the 7-
year progression of AMD [53]. Data from two small case control
studies also showed an association with Chlamydia pneumoniae,
but not other pathogens with AMD [63,64]. In a previous study
authors reported racial/ethnic differences in the frequency of early
AMD with decreasing overall frequencies found in whites (5.4%),
Chinese (4.6%), Hispanics (4.2%), and blacks (2.4%) in the Multi
Ethnic Study of Atherosclerosis [65]. The reasons for these racial/
ethnic differences, especially between whites and blacks, were not
explained by known risk factors such as cigarette smoking, history
of alcohol drinking, BMI, hypertension, diabetes status, and
markers of subclinical cardiovascular disease [65]. Van de Ven
et al. showed that a history of inﬂammatory diseases or use of anti-
inﬂammatory agents, or biomarkers of inﬂammation and related
processes also did not explain racial/ethnic differences in
prevalence of early AMD among the different racial/ethnic groups
[66]. Authors found thatwhites, blacks, andHispanicswhowere all
homozygous for the complement factor H (CFH) Y402H CC variant
genotype had the highest frequencies of early AMD comparedwith
those with the CFH Y402H TT wild genotype. The CFH Y402H CC
variant genotype distributions varied among the racial/ethnic
groups and did explain some of the difference in early AMD
prevalence for Chinese and for Hispanics but did not explain the
difference in AMD prevalence between whites and blacks
[66]. Genetic studies have implicated roles for the immune
system, particularly abnormalities in the complement system in
pathogenesis and severity of AMD. Although patients with AMD do
not have signs of overt ocular inﬂammation, histologic studies
have shown the presence of macrophages, lymphocytes, and mast
cells, as well as ﬁbroblasts, associated with both atrophic lesions
and with neovascularization of the retina [67]. Over the past
decade, studies has found that inﬂammation play a large role in the
pathogenesis of age-related macular degeneration (AMD). In fact,
the main genetic changes (polymorphism) associated
with AMD were found to be genes that regulate inﬂammation,
most notably CFH [68]. Complement factor H is a circulating
protein that inhibits directly or indirectly the three complement
activation pathways. In patients with early and late AMD, many
CFH polymorphisms have been described [69]. With abnormal
CFH, complement system downregulation is defective and excess
inﬂammation may result. Additionally, histological analysis of
drusen revealed the presence of complement factors and the
terminal membrane attack complex [70]. It is still unknown
whether those complement factors are systemically or locally
produced in the retina [71]. Chronic subclinical local inﬂammation
of the retina in AMD patients may trigger and/or sustain the
damaging process [59,60]. Despriet et al. found that markers of
inﬂammation, such as serum C-reactive protein (CRP) are related
to AMD only in carriers of CFH Y402H variants [72]. Multiple
studies have assessed the role of genetic variants on AMD
development and progression, especially with CFH and age-related
maculopathy susceptibility 2 (ARMS2) genes, the two major
susceptibility genes for AMD. CFH Y402H heterozygotes allele
conferred 4.6-fold increased risk for AMD and the homozygotes a
7.4-fold increased risk, as compared with the homozygous non-
risk genotype [73]. Individuals heterozygotous for ARMS2 A69S
allele conferred 2.7-fold increased risk of AMD compared with
wild-type homozygous allele, whereas a 8.2-fold increased risk is
associated with the homozygous risk allele. An additive effect
of CFH Y402H and LOC387715A69S is seenwith 50-fold increase in
the risk of AMD in subjects homozygous for both risk alleles[74]. CFH, ARMS2 these two allelic variants contribute to late AMD
in more than 80% of cases [74,75]. Other genes that harbor
established risk variants for AMD include the complement factor B
(CFB), complement component 2 (C2), complement component 3
(C3), complement factor I (CFI), and the apolipoprotein E (APOE)
genes [76]. The last stage of the complement inactivation
(classical and lectyne) is the occurrence of the membrane attack
complex (MAC) [77]. Convertase C3 is crucial here, and nine
mutations of the single nucleotide, including R102G by its
inﬂuence on cellular disintegration, are closely connected with
exudative AMD [77].
The neovascular form of age-related macular degeneration
(AMD), also known as wet AMD, is characterized by the formation
of subretinal choroidal neovascularization (CNV) and is the cause
of most cases of blindness in the elders. Wet AMD is the major
cause of severe vision loss in developed nations and is estimated to
affect > 2.5 million people worldwide [78,79]. The patients
affected by exudative AMD often experience rapid loss of ﬁne
resolution central vision over several months, and early visual
stabilization is a key issue in preserving visual acuity [80]. Angio-
genesis is the development of new blood vessels from pre-existing
vessels and whilst being a crucial process in normal physiology, it
is an important pathogenic process in both benign and malignant
disease [81]. A lot of markers, both stimulating and inhibiting can
inﬂuence on this process. Activators of angiogenesis include: VEGF,
nitric oxide (NO), integrins: a5b1, avb3 and avb5, transforming
growth factor beta 1 (TGFb1) and its receptors, growth factors:
acidic ﬁbroblast growth factor (aFGF), basic ﬁbroblast growth
factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth
factor I (IGF-I), platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), hypoxia-inducible factor 1 alpha (HIF-1a), IL-
8, IL-1, prostaglandin (PGE 1, PGE 2, PGF), erythropoietin,
histamine, bradykinin, tumour necrosis factor alpha (TNFa)
[82,83]. Abnormal angiogenesis is a hallmark of diseases such as
cancer, chronic inﬂammation and also the neovascular form of
AMD [84,85]. Choroidal neovascularization (CNV) represents the
growth of new blood vessels from the choroid into the subretinal
pigment epithelium. Several proangiogenic factors are consistently
upregulated during CNV formation, particularly two members of
the vascular endothelial growth factor (VEGF) family, VEGF-A and
placental growth factor (PlGF) [84,86]. These factors activate
quiescent endothelial cells and promote cell proliferation, migra-
tion and vascular permeability [84].
5. Treatment of AMD
While a treatment for geographical atrophy (GA) remains to be
established, treatments for neovascular AMD using photodynamic
therapy and antivascular endothelial growth factors exist.
Currently, the only approved treatment for dry AMD is the use
of AREDS formulation [17,58,87]. In the near future, it is likely that
the treatment of dry AMD will be a combination of different drugs
that will target the different pathways involved in the pathogen-
esis and progression of dry AMD [88]. Firstly pharmacological
targeting of components involved in dry AMD pathogenesis is
prevention of photoreceptors and RPE cells loss. Ciliary neuro-
trophic factor (CNTF) is a potent neurotrophic factor that slows
down loss of photoreceptors in various animal models of retinal
degeneration [89], and there are evidences of its efﬁcacy in human
retinitis pigmentosa [90]. Alpha-2 adrenergic receptor is present in
the mammalian retina and brimonidine tartrate (Allergan Inc.,
USA, an alpha-2 adrenergic receptor agonist has been shown to
protect retinal ganglion cells, bipolar cells, and photoreceptors in
numerous models of experimental nerve injury, including retina
ischemia, ocular hypertension, retinal phototoxicity, and partial
optic nerve crush [91]. Other authors in an animal model found
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Laboratories Inc., USA) protects photoreceptors and RPE cells from
photo-oxidative stress by decreasing microglia activation/recruit-
ment and complement deposition in the outer retinax [92]. The
analysis of the drusen in patients with Alzheimer disease treated
with glatiramer acetate (an immunomodulatory drug currently
used to treat multiple sclerosis) showed that the drug reduces
drusen area. Speciﬁcally in patients with dry AMD, glatiramer
acetate shrank or eliminate more drusen than did sham treatment
[93].
Secondly pharmacological targeting of components involved in
dry AMD pathogenesis is suppression of inﬂammation. It is likely
that if inﬂammation will be reduced, development or progression
of AMDwill also be reduced. Inﬂammatory elements are present in
drusen, such as components of the complement system, acute-
phase proteins, proteins that modulate the immune response,
lipofuscin, and dendritic cells [71]. In an animal model study
authors found that ﬂuocinolone acetonide is a potent corticoster-
oid that presented a neuroprotective effect by dampening retinal
neuroinﬂammation [94,95]. Several therapeutic agents involved in
the complement cascade are under investigation [88]. POT-4
(Potentia Pharmaceuticals, USA) is a synthetic peptide that
reversibly binds complement factor C3 and inhibits activation
of the complement cascade (ClinicalTrials.gov number,
NCT00473928). Eculizumab (Alexion Pharmaceuticals, USA) is a
humanized IgG antibody that selectively inhibits the cleavage of C5
factor into C5a and 5b (ClinicalTrials.gov number, NCT00935883).
ARC1905 (Ophthotech Corp., USA) is an aptamer that is a potent
and selective inhibitor of factor C5 of the complement cascade
(ClinicalTrials.gov number, NCT 00950638). FCFD4514S (Genen-
tech Inc., USA) is a human monoclonal antibody that inhibits
complement factor D, a protein involved in the alternative
complement pathway (ClinicalTrials.gov numbers, NCT
00973011) [88]. Treatment of dry AMD still remains a challenge.
Currently, the only approved treatment for dry AMD is the use of
Age-Related Eye Disease Study (AREDS)-based vitamin supple-
ments, which does not halt the vision loss but lowers the risk of
developing advanced stages of AMD (either geographic atrophy or
neovascular AMD) and reduces visual loss in people at risk for the
disease [17,87]. The AREDS established that antioxidant vitamin
and mineral supplementation (AREDS formulation) consisting of
b-carotene (15 mg), vitamins C (500 mg) and E (400 IU), and zinc
(as zinc oxide 80 mg), along with copper (as cupric oxide 2 mg)
slowed progression of AMD in individuals at high risk of
developing advanced AMD [87]. Recent analyses demonstrate
that the beneﬁcial effects are restricted mostly to preventing the
progression to neovascular AMD [69].
The arsenal of VEGF blockers has evolved over time, with newer
generations offering potentially improved anti-angiogenic activity
by increasing their afﬁnity for VEGF-A, and/or the number of VEGF-
isoforms and family members that they inhibit. Pegaptanib
(MacugenTM, Eyetech, Inc.) is an aptamer that selectively binds
to and neutralizes VEGF-A165, but not VEGF-A121, and was the ﬁrst
anti-VEGF therapy approved for the treatment of wet AMD
[96]. The development of new agents for wet AMD has focused
on both improving efﬁcacy and extending the duration of action in
comparison with the commonly used anti-VEGF drugs ranibizu-
mab and bevacizumab, which are considered the standard drugs.
Ranibizumab is a monoclonal humanized antibody fragment and
bevacizumab is a whole monoclonal antibody, and both show a
high binding afﬁnity for all isoforms of VEGF. These agents appear
to have similar efﬁcacy proﬁles andmechanisms of action, i.e., they
block the extracellular availability of VEGF which can arrest
choroidal angiogenesis and reduce vascular permeability for a
limited period of time [97,98]. Aﬂibercept, or VEGF Trap-eye, is a
novel compound derived from the native VEGF receptor (VEGFR)that binds to all VEGF and VEGF-B isoforms as well as to PlGF [99].
It may be considered an attractive alternative to other anti-VEGF
agents because it appears to offer visual outcomes similar to
ranibizumab and bevacizumabwith a longer duration of action. For
the ﬁrst time, an anti-VEGF drug can be given at 2-month intervals
with results comparable to ranibizumab given every 4 weeks
[100]. The data demonstrate that VEGF trap binds human VEGF-A
with higher afﬁnity and a signiﬁcantly faster association rate, thus
neutralizing VEGF-A with greater potency than ranibizumab or
bevacizumab [99].
Projections over the next decade suggest that the number of
prevalent cases of late AMD will increase steadily by a third by
2020 due to population ageing. These evidence-based estimates
can be used to help plan social and healthcare provision for the
present and the future.
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